DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
about
Tyrosine kinase - Role and significance in Cancer.An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo.Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.Denileukin diftitox: a novel immunotoxin.Targeted treatment for chronic lymphocytic leukemia.Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.Antibody-cytotoxic agent conjugates for cancer therapy.Use of bacteria in anti-cancer therapies.Tumor control versus adverse events with targeted anticancer therapies.Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma.
P2860
Q24791430-89BEB0A9-3445-4E20-80A4-26575122F4E3Q33529309-F7ED4ABB-17D3-486F-B516-49113D2EE1FCQ34558230-60AF823E-61EA-45BB-8941-C8D584F8010CQ34943798-039A50A8-18B2-4D6E-BB14-092770AA9EC8Q35007337-B9E35588-90FA-4A4E-9265-3725C41A7D57Q35599741-3C79178E-B29A-44CA-880B-A6A305D7656CQ36226862-C5B2FCA0-5940-481A-9BA6-4779CC438E71Q36316831-7FB52CAE-F968-4FFA-BA08-77657BC4C7E2Q36348880-E9051807-EE2A-4CA3-82F8-6059EA2FF953Q37969899-57AD4212-B485-4D51-806D-2D5784F9F1B2Q49540233-D8968081-571F-4F9E-AA03-11074E6FB326Q53610618-47A2079B-1951-4A36-B69B-A52BACD09035
P2860
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@ast
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@en
type
label
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@ast
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@en
prefLabel
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@ast
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@en
P2093
P2860
P356
P1476
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
@en
P2093
Bayard L Powell
Donald R Fleming
Ronald Gartenhaus
P2860
P304
P356
10.1517/14712598.3.1.179
P407
P577
2003-02-01T00:00:00Z